Search

Self-microemulsifying drug delivery system (SMEDDS) of lovastatin was aimed at overcoming the problems of poor solubility and bioavailability. The formulation strategy included selection of oil phase based on saturated solubility studies and surfactant and co-surfactant screening on the basis of their emulsification ability. Ternary phase diagrams were constructed to identify the self-emulsifying region. Capryol 90 (20 %) as oil, Cremophore RH40 (40 %) as surfactant and Transcutol P (40 %) as co-surfactant were concluded to be optimized components. The prepared SMEDDS was characterized through its droplet size, zeta potential, emulsification time, rheological determination and transmission electron microscopy. The optimized formulation exhibited 94 % in vitro drug release, which was significantly higher than that of the drug solution. In vivo studies using the Triton-induced hyperlipidemia model in Wistar rats revealed considerable reduction in lipid levels compared to pure lovastatin. The study confirmed the potential of lovastatin SMEDDS for oral administration.

Self-microemulsifying drug delivery system (SMEDDS) of lovastatin was aimed at overcoming the problems of poor solubility and bioavailability. The formulation strategy included selection of oil phase based on saturated solubility studies and surfactant and co-surfactant screening on the basis of their emulsification ability. Ternary phase diagrams were constructed to identify the self-emulsifying region. Capryol 90 (20 %) as oil, Cremophore RH40 (40 %) as surfactant and Transcutol P (40 %) as co-surfactant were concluded to be optimized components. The prepared SMEDDS was characterized through its droplet size, zeta potential, emulsification time, rheological determination and transmission electron microscopy. The optimized formulation exhibited 94 % in vitro drug release, which was significantly higher than that of the drug solution. In vivo studies using the Triton-induced hyperlipidemia model in Wistar rats revealed considerable reduction in lipid levels compared to pure lovastatin. The study confirmed the potential of lovastatin SMEDDS for oral administration., U svrhu povećanja topljivosti i bioraspoloživosti lovastatina dizajniran je i evaluiran samomikroemulzifikacijski sustav za isporuku lijeka (SMEDDS). Uljna faza izabrana je na temelju studija topljivosti, a surfaktant i kosurfaktant na temelju njihove sposobnosti emulzifikacije. Samoemulzifikacijsko područje određeno je pomoću ternarnih faznih dijagrama. Kao optimalni sastojci pokazali su se Kapriol 90 (20 %) kao uljna faza, Cremophore RH40 (40 %) kao surfaktant i Transcutol P (40 %) kao kosurfaktant. Pripravljenom SMEDDS određena je veličina kapljica, zeta potencijal, emulzifikacijsko vrijeme, reološka svojstva i transmisija u elektronskoj mikroskopiji. In vitro se iz optimiziranog pripravka oslobodilo 94 % ljekovite tvari, što je bilo značajno više nego iz otopine lijeka. Studije in vivo na Wistar štakorima kojima je hiperlipidemija inducirana Tritonom pokazale su da SMEDDS značajno više snižava razinu lipida nego čisti lovastatin. Istraživanja su potvrdila da je lovastatin SMEDDS pripravak pogodan za peroralnu primjenu.